Rezvilutamide clinical trials
Also written SHR3680.
How each study uses rezvilutamide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the rezvilutamide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
24 studies that test it; most in 2023 (8)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 3 |
| 2023 | 8 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 12
Jiangsu HengRui Medicine Co., Ltd. (11) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (4) · Fudan University (3) · Atridia Pty Ltd. (1) · Zhujiang Hospital (1) · Fujian Medical University Union Hospital (1) · Jianbin Bi (1) · Peking University First Hospital (1)
Often tested with
Tested in the same studies.
Fluzoparib (4) · Camrelizumab (2) · Trastuzumab rezetecan (1) · Tizetatug rezetecan (1) · Leuprolide (1) · Abiraterone Acetate (1) · Abiraterone (1) · Prednisolone (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Rezvilutamide is the comparator. A study of two new drugs counts under both.
- 1Docetaxel · The First Affiliated Hospital with Nanjing Medical University
Reaching primary completion within a year · 7, 1 in phase 3
Studies that test rezvilutamide, phase 3 first.
- Mar 2027A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate CancerPhase 3 · Jiangsu HengRui Medicine Co., Ltd.
- Dec 2026A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular TypingPhase 2 · Fudan University
- Dec 2026Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate CancerPhase 2 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Feb 2027Rezvilutamide for High-Risk Prostate Cancer After SurgeryNot applicable · Fujian Medical University Union Hospital
- Mar 2027Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate CancerPhase 2 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- May 2027Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical ProstatectomyPhase 2 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Jun 2027Clinical Study of Rezvilutamide Combined With Docetaxel Chemotherapy in the Treatment of Abiraterone-Resistant Prostate CancerNot applicable · Zhujiang Hospital
Studies
Open first, then newest update. How each study uses rezvilutamide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 24
- Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical ProstatectomyRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07711314Written as Rezvilutamide Tablets
- A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate CancerRecruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT07241416Written as Rezvilutamide Tablets
- Rezvilutamide for High-Risk Prostate Cancer After SurgeryNot yet recruitingNot applicableFujian Medical University Union HospitalNCT07444983Written as Rezvilutamide and Leuprorelin
- Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct CarcinomaRecruitingPhase 2Peking University First HospitalNCT06348264Written as Rezvilutamide
- Clinical Study of Rezvilutamide Combined With Docetaxel Chemotherapy in the Treatment of Abiraterone-Resistant Prostate CancerEnrolling by invitationNot applicableZhujiang HospitalNCT07112209Written as Rezvilutamide combined with docetaxel
- Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate CancerRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT06305832Written as Rezvilutamide
- Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate CancerNot yet recruitingPhase 2Jianbin BiNCT06134271Written as Rezvilutamide
- Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPCRecruitingPhase 3The First Affiliated Hospital with Nanjing Medical UniversityNCT05956639Written as 6-month course of antiandrogen drugs
- An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)Not yet recruitingPhase 1/2Fudan UniversityNCT05928780Written as A1:SG with SHR3680
- A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer SubjectsRecruitingPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT05607693Written as SHR3680 tablets
- Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate CancerRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT05753566Written as Rezvilutamide
- Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate CancerRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT05406999Written as Rezvilutamide
- Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin HydrochlorideCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04621669Written as SHR3680
- A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical ProstatectomyTerminatedPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT05009290Written as SHR3680
- A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular TypingActive, not recruitingPhase 2Fudan UniversityNCT05924256Written as SHR 3680 + leuprolide
- A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPCTerminatedPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT04102124Written as SHR3680
- The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and OmeprazoleCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04676035Written as Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680
- An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy ParticipantsStatus unknownPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04631549Written as SHR3680
- Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerStatus unknownPhase 2Fudan UniversityNCT04355858Written as SHR3680
- A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate CancerActive, not recruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT03520478Written as SHR3680
See all 24 studies that test rezvilutamide →
Given beside what is tested · 5 — rezvilutamide is usual care or a partner of the new treatment
- A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate CancerRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT07407283Written as Rezvilutamide
- Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate CancerNot yet recruitingPhase 2Fudan UniversityNCT07490210Written as Rezvilutamide + ADT
- A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate CancerRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07230106Written as SHR3680 Tablet
- Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)RecruitingPhase 2The First Affiliated Hospital of Xiamen UniversityNCT06387056Written as Rezvilutamide
- A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPCTerminatedPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT03741712Written as SHR3680
As the comparator · 1 — what is tested is compared with rezvilutamide
Codes
What other systems call rezvilutamide · ClinicalTrials.gg INT015360
- UNII (FDA) 70FJN2AW22REZVILUTAMIDEConfirmed FDA, Wikidata
- Wikidata Q101063961rezvilutamideConfirmed FDA, Wikidata
- NCI Thesaurus C175852RezvilutamideOne source FDA
- DrugBank DB19133One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 70FJN2AW22 | REZVILUTAMIDE | Confirmed FDA, Wikidata |
| Wikidata | Q101063961 | rezvilutamide | Confirmed FDA, Wikidata |
| NCI Thesaurus | C175852 | Rezvilutamide | One source FDA |
| DrugBank | DB19133 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.